An underarm lotion that boosts testosterone in men may soon hit stores.
Melbourne-based Acrux has signed a deal worth 367 million dollars, permitting US pharmaceutical company Eli Lilly the right to sell the underarm sex-drive testosterone lotion.
Eli Lilly will get worldwide rights to market the Axiron treatment, as per the agreement.
The Axiron treatment is used in the treatment of testosterone deficiency in men over 45 years old.
A clinical trial found Axiron bring testosterone levels to normal in 84 per cent of men after four months, Bloomberg reported.
"You've clearly got an aging population all around the world. here is far greater awareness around men's health in general. It's being spoken about more readily," the Sydney Morning Herald quoted Acrux chief executive Richard Treagus, as saying.
President of Lilly's Bio-Medicines Bryce Carmine, in the ASX statement, said:
"Lilly hopes to leverage our experience in men's health to advance both the science and clinical outcomes for men with low testosterone.
"Axiron has the potential to be the first testosterone solution to be applied via an underarm applicator, for patients who have testosterone deficiency."